logo

Glyco-engineered Biopharmaceuticals

Our glyco-engineered biopharmaceuticals allow us to address tumor specific glyco-epitope targets giving the potential for powerful anti-cancer activity and reduced side-effects

More
Biopharmaceuticals Pipeline Glycotope’s mature pipeline of first-in-class and best-in-class biopharmaceuticals Find out more
Biopharmaceuticals Services Glycotope’s unique combination of development and production expertise Find out more

Using world-leading glycobiology expertise to improve outcomes for patients

About
An introduction to our company, experienced leadership and Board
Technology
Learn how we are leveraging our proprietary technologies to drive innovation
PankoMab-GEX®
Our first-in-class antibody against a tumor-specific carbohydrate-protein epitope
Careers
Join us
News
22. Dec
2017
Glycotope Initiates Phase Ib Trial of Combination of Proprietary Anti-Tumor Antibodies

Berlin, Germany, 22 December 2017 – Glycotope GmbH, a clinical-stage immuno-oncology company built on […]

30. Oct
2017
Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing

Tokyo, Japan, Basking Ridge, NJ, and Berlin, Germany – (October 30, 2017) – Daiichi […]

See All News
Events
30-04 May
2018
14th Annual PEGS Boston
01-05 Jun
2018
2018 ASCO Annual Meeting
See All Events
Get in Touch
  • About Us
  • Technologies
  • Biopharmaceuticals Pipeline
  • Biopharmaceuticals Services
  • News
  • Events
  • Contact
  • Careers
  • Terms of Business / Imprint

Glycotope GmbH

Robert-Roessle-Str. 10
13125 Berlin
Germany

E / contact@glycotope.com
T / +49 (0) 30 9489 2600

logo
Site Index Terms of Business Privacy Policy Cookies Legal
© Copyright 2018 GLYCOTOPE GmbH. All rights reserved.
  • About Us
    • Management
  • Technologies
    • Scientific Publications
  • Biopharmaceuticals Pipeline
    • Gatipotuzumab (previously known as PankoMab-GEX®)
    • Tomuzotuximab (previously known as CetuGEX®)
    • TrasGEX®
    • FSH-GEX®
  • Biopharmaceuticals Services
    • Cell Lines
    • Process Development
    • PTM
    • Immunomonitoring
  • News
  • Events
  • Contact
  • Careers
  • Terms of Business / Imprint